MANE
NYSEVeradermics Incorporated
News25/Ratings4
News · 26 weeks31-50%
2025-10-262026-04-19
Mix3190d
- Insider15(48%)
- Other6(19%)
- SEC Filings4(13%)
- Analyst4(13%)
- Offering2(6%)
Latest news
25 items- SECSEC Form 10-K filed by Veradermics Incorporated10-K - Veradermics, Inc (0001827635) (Filer)
- SECVeradermics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Veradermics, Inc (0001827635) (Filer)
- PRVeradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical UpdatesEnrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss Mark Neumann, seasoned biopharmaceutical commercial leader with more than 30 years of experience launching and scaling blockbuster therapies, appointed Chief Commercial and Strategy Officer Upsized IPO of $294.8 million closed in February 2026; pro forma cash, cash equivalents and marketable securities expected to fund planned operations into 2029, through multiple anticipated Phase 3 readouts and
- PRVeradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual MeetingVeradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026. The data to be presented include a blinded, retrospective investigator global assessment conducted by six independent dermatologists regarding the comparative perceived efficacy of VDPHL01 versus existing minoxidil formulations and the clinical potential of VDPHL01. In addition, two presentations will characteriz
- PRVeradermics to Participate in Upcoming March Investor ConferencesVeradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL Reid Waldman, M.D., CEO of Veradermics, will participate in a fireside chat at 4:20 p.m. ET. Jefferies Biotech on the Beach Summit on Wednesday, March 11 in Miami, FL A live webcast of the Leerink conference fireside chat will be available on the "Events" page of the "Investors" section of the
- ANALYSTCantor Fitzgerald initiated coverage on VeradermicsCantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight
- ANALYSTJefferies initiated coverage on Veradermics with a new price targetJefferies initiated coverage of Veradermics with a rating of Buy and set a new price target of $75.00
- ANALYSTCitigroup initiated coverage on Veradermics with a new price targetCitigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00
- ANALYSTLeerink Partners initiated coverage on Veradermics with a new price targetLeerink Partners initiated coverage of Veradermics with a rating of Outperform and set a new price target of $75.00
- INSIDERAmendment: Director Childs John W bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)4/A - Veradermics, Inc (0001827635) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Veradermics IncorporatedSCHEDULE 13G - Veradermics, Inc (0001827635) (Subject)
- PRNYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening BellNYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on February 12th Markets are higher after mixed reactions to yesterday's hotter than expected Jobs Report as the Bureau of Labor Statistics reported that the U.S. economy added 130,000 jobs.Forgent Power Solutions (NYSE:FPS) is celebrating its early February IPO this morning with shares having jumped 22% since trading
- SECSEC Form SCHEDULE 13D filed by Veradermics IncorporatedSCHEDULE 13D - Veradermics, Inc (0001827635) (Subject)
- INSIDERDirector Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERNew insider Suvretta Capital Management, Llc claimed ownership of 3,886,317 shares (SEC Form 3)3 - Veradermics, Inc (0001827635) (Issuer)
- PRVeradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossThis marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the second half of 2026 VDPHL01, if approved, has the potential to be the first and only non-hormonal oral FDA approved treatment for men and women with pattern hair loss, a condition affecting an estimated 50 million men and 30 million women in the United States Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing
- INSIDERSEC Form 4 filed by Director Pance Katarina4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERDirector Grant-Kels Jane M. converted options into 2,455 shares (SEC Form 4)4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERSEC Form 4 filed by Director Friedman David Matthew4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERDirector Coric Vlad converted options into 638,262 shares and bought $1,999,982 worth of shares (117,646 units at $17.00), increasing direct ownership by 913% to 129,939 units (SEC Form 4)4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERDirector Childs John W converted options into 1,907,889 shares and bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERLarge owner Longitude Capital Partners V, Llc converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERDirector Enright Patrick G converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Greco Michael V.4 - Veradermics, Inc (0001827635) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Neumann Mark4 - Veradermics, Inc (0001827635) (Issuer)